Literature DB >> 11413339

Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity.

A M Harandi1, B Svennerholm, J Holmgren, K Eriksson.   

Abstract

Using a combination of gene-targeted mice and neutralizing antibodies, we showed that interleukin-12 (IL-12) and IL-18 are important in the innate control of genital herpes simplex virus type 2 infection but were not found to be critical, either singly or in combination, for the development of a protective gamma interferon-mediated immune response.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11413339      PMCID： PMC114395          DOI： 10.1128/JVI.75.14.6705-6709.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  43 in total

1.  A novel transcription factor, T-bet, directs Th1 lineage commitment.

Authors:  S J Szabo; S T Kim; G L Costa; X Zhang; C G Fathman; L H Glimcher
Journal:  Cell       Date:  2000-03-17       Impact factor: 41.582

2.  IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells.

Authors:  K Tominaga; T Yoshimoto; K Torigoe; M Kurimoto; K Matsui; T Hada; H Okamura; K Nakanishi
Journal:  Int Immunol       Date:  2000-02       Impact factor: 4.823

3.  IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes.

Authors:  K Barbulescu; C Becker; J F Schlaak; E Schmitt; K H Meyer zum Büschenfelde; M F Neurath
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

4.  Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice.

Authors:  K Kawakami; Y Koguchi; M H Qureshi; Y Kinjo; S Yara; A Miyazato; M Kurimoto; K Takeda; S Akira; A Saito
Journal:  FEMS Microbiol Lett       Date:  2000-05-01       Impact factor: 2.742

5.  Humoral response to herpes simplex virus is complement-dependent.

Authors:  X J Da Costa; M A Brockman; E Alicot; M Ma; M B Fischer; X Zhou; D M Knipe; M C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Nitric oxide and macrophage antiviral extrinsic activity.

Authors:  F Benencia; M C Courreges
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

Review 7.  Regulation of the IL-12/IL-12R axis: a critical step in T-helper cell differentiation and effector function.

Authors:  F Sinigaglia; D D'Ambrosio; P Panina-Bordignon; L Rogge
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

8.  IL-12-independent Th1-type immune responses to respiratory viral infection: requirement of IL-18 for IFN-gamma release in the lung but not for the differentiation of viral-reactive Th1-type lymphocytes.

Authors:  Z Xing; A Zganiacz; J Wang; M Divangahi; F Nawaz
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

9.  Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii.

Authors:  G Cai; R Kastelein; C A Hunter
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

10.  Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection.

Authors:  K Ohkusu; T Yoshimoto; K Takeda; T Ogura; S Kashiwamura; Y Iwakura; S Akira; H Okamura; K Nakanishi
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441
View more
  38 in total

1.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  RNA-dependent protein kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex virus type 2.

Authors:  Daniel J J Carr; Lisa Tomanek; Robert H Silverman; Iain L Campbell; Bryan R G Williams
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 3.  Herpes simplex virus and the chemokines that mediate the inflammation.

Authors:  D J J Carr; L Tomanek
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

Review 4.  Interleukin 12 a key immunoregulatory cytokine in infection applications.

Authors:  Therwa Hamza; John B Barnett; Bingyun Li
Journal:  Int J Mol Sci       Date:  2010-02-26       Impact factor: 5.923

5.  Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.

Authors:  Alison J Johnson; Michelle H Nelson; Melanie D Bird; Chin-Fun Chu; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2009-11-25       Impact factor: 4.054

6.  Chemokines and Chemokine Receptors Critical to Host Resistance following Genital Herpes Simplex Virus Type 2 (HSV-2) Infection.

Authors:  M Thapa; D J J Carr
Journal:  Open Immunol J       Date:  2008

7.  Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.

Authors:  Ali A Ashkar; Stefan Bauer; William J Mitchell; Jeff Vieira; Kenneth L Rosenthal
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity.

Authors:  Patrick C Reading; Geoffrey L Smith
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Ethanol inhibits LPS-induced signaling and modulates cytokine production in peritoneal macrophages in vivo in a model for binge drinking.

Authors:  Stephen B Pruett; Ruping Fan
Journal:  BMC Immunol       Date:  2009-09-18       Impact factor: 3.615

10.  FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.

Authors:  William A Rose; Chris L McGowin; Richard B Pyles
Journal:  Virol J       Date:  2009-11-10       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.